-
Mashup Score: 2A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development - 8 month(s) ago
YTB323, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, retains T-cell stemness after a manufacturing process time of less than 2 days and demonstrates clinical antitumor activity at significantly lower doses than traditionally manufactured CAR T cells.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Validate User - 8 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this week's Cancer Discovery #ResearchWatch: Epitope Editing Prevents Off-Tumor Toxicity of #CARTcell Therapy in #AML, a summary of the paper by @CasiratiG, @Genovese_Lab et al. https://t.co/YJQqp6bdzn @DFBC_PedCare https://t.co/z0m5TJL3r0
-
-
Mashup Score: 0Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma - 8 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Recs on prevention of infections during #CARTcell & bispecific antibody Tx in myeloma [6/7/23] @MeeraMohanMD @rajshekharucms @SusanBal9 Nellore @MMBaljevicMD @adsouza_md @DrPappasID @BerdejaJesus @nsc_natalie @End_myeloma @BrJHaem https://t.co/Ay6wRTWBXU #mmsm #IDonc
-
-
Mashup Score: 1Bursting Tumor Bubbles to Improve CAR T-cell Therapy - 8 month(s) ago
Abstract. Chimeric antigen receptor (CAR) T cells have had dramatic success in B-cell malignancies, but this efficacy has not yet translated to more common solid tumors. In this issue of Cancer Research, Zhong and colleagues demonstrated that tumor-derived small extracellular vesicles (sEV) contain CAR target antigens like mesothelin, enabling them to preferentially interact with and suppress the activity of CAR T cells in vivo. PD-L1 in tumor-derived sEVs increased upon CAR T-cell infusion and induced PD-L1–dependent suppression of CAR T cells that could be completely reversed by PD-L1 blockade. Strategies to inhibit sEV secretion, via genetic manipulation of tumor cells or pharmacologic inhibition, significantly improved CAR T-cell accumulation, function, and antitumor activity in vivo, suggesting that therapeutic targeting of sEV secretion could be a promising new approach to improving the efficacy of CAR T-cell therapy.See related article by Zhong et al., p. 2790
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Read the commentary— Bursting Tumor Bubbles to Improve #CARTcell Therapy, by Ortiz-Espinosa and @sriv4000. https://t.co/2e6URJLvFj @fredhutch https://t.co/tJNGFhXhCR https://t.co/GK6ahPQaTx
-
-
Mashup Score: 1Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study - 8 month(s) ago
In the single-arm, open-label, multicenter, phase 2 PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom hematopoietic stem cell transplantation (HSCT) was not intended resulted in high response rates, durable responses, and a safety profile consistent with previous reports. Here, we analyzed changes in health-related quality of life (HRQOL) in patients who received liso-cel in PILOT. Patients received liso-cel, an autologous, CD19-directed, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells, for a total target dose of 100 × 10⁶ CAR+ T cells. HRQOL, a secondary endpoint of PILOT, was assessed as prespecified using 3 patient-reported outcome instruments (EORTC QLQ-C30; FACT-LymS; EQ-5D-5L). Evaluable datasets for the EORTC QLQ-C30, FACT-LymS, EQ-5D-5L health utility index, and EQ-5D visual ana
Source: haematologica.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell #DLBCL #lymphoma: patient-reported outcomes #PROM from the PILOT study #CARTcell #VBHC #HRQoL https://t.co/89zdMfhuJJ
-
-
Mashup Score: 3
multicenter retrospective observational study, we studied the patient-individual journey from CAR-T indication to infusion, baseline features, and survival outcomes in 374 patients treated with tisagenlecleucel (tisa-cel) or axicabtagene-ciloleucel (axi-cel) in EU and the United States (US). Compared with US patients, EU patients had prolonged indication-to-infusion intervals (66 versus 50 d; P < 0.001) and more commonly received intermediary therapies (holding and/or bridging therapy, 94% in EU versus 74% in US; P < 0.001). Baseline lactate dehydrogenase (LDH) (median 321 versus 271 U/L; P = 0.02) and ferritin levels (675 versus 425 ng/mL; P = 0.004) were significantly elevated in the EU cohort. Overall, we observed inferior survival in EU patients (median progression-free survival [PFS] 3.1 versus 9.2 months in US; P < 0.001) and with tisa-cel (3.2 versus 9.2 months with axi-cel; P < 0.001). On multivariate Lasso modeling, nonresponse to bridging, elevated ferritin, and increased C-r
Source: journals.lww.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Inferior Outcomes of EU 🇪🇺 vs US 🇺🇸Patients Treated With CD19 #CARTcell for Relapsed/Refractory Large B-cell #Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CART Product #lymsm https://t.co/g5OlXsdF2K
-
-
Mashup Score: 0Prognostic value of early bone marrow and PET MRD assessment in CAR-T therapy for multiple myeloma - 8 month(s) ago
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the prognostic value of early bone marrow measurable residual disease (MRD) assessment following CAR-T therapy in multiple myeloma. A recent study found that patients who achieve MRD negativity and free light chain clearance one month after CAR-T have better outcomes. Conversely, MRD positivity and residual free light chain levels after one month indicate a higher risk of relapse and a lower rate of durable response. A follow-up study demonstrated that negative results in both early bone marrow and PET MRD assessments serve as the strongest prognostic indicator for CAR-T therapy outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO23 | @YiLinMDPhD of @MayoClinic discusses a recent study exploring the prognostic value of early bone marrow MRD assessment following CAR-T therapy in patients with multiple myeloma. Watch here👇: https://t.co/UfhLNPeWbv #MMsm #ImmunoOnc #CARTcell
-
-
Mashup Score: 0Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL - 8 month(s) ago
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tune in to our most recent podcast, where you'll hear about the value and curative potential of CAR-T cells & bispecific antibodies in R/R DLBCL from @AnnaSureda5, @gloria_iacoboni & @mana1981: 🎧 https://t.co/QUUDvxzJPe #LymSM #CARTcell #HemOnc https://t.co/jhSIk25aBy
-
-
Mashup Score: 0Identifying and managing patients at high risk of developing toxicities following CAR-T therapy - 8 month(s) ago
Kai Rejeski, MD, LMU Munich, Munich, Germany, provides insights into the management of toxicities associated with CAR-T therapy including hematological toxicities, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Dr Rejeski emphasizes the need to develop personalized approaches based on a patient’s risk to develop such toxicities, explaining the benefit of using escalated supportive measures and prophylaxis in patients with a high risk of developing CAR-T-associated toxicity. He also explains that patients who experience hematological toxicities should receive a hematopoietic stem cell boost as early as possible if available. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our recent interview with @KRejeski, who briefly discusses the importance of identifying & managing patients at high risk of developing toxicities following CAR-T therapy: 🎥 https://t.co/4LxFlNeX2s #EHA2023 #HemOnc #ImmunoOnc #CARTcell
-
-
Mashup Score: 1Outcomes of COVID-19 3-Dose Vaccination in Immunocompromised Patients With Hematologic Cancers - 8 month(s) ago
This cohort study assesses neutralizing antibody concentrations following a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers to levels obtained in healthy individuals after the standard 2-dose vaccination schedule.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for #COVID19 [Aug 11, 2022] Haggenburg et al. @JAMAOnc https://t.co/YYUILPAip5 #COVID19Vaccine #IDonc #bmtsm #leusm #lymsm #mmsm #mpnsm #CARTcell https://t.co/poK42vd2Ls
-
From the September issue: A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced #CARTCell Efficacy in Preclinical and Early Clinical Development, by @mike_dickinson1 et al. https://t.co/pAt3b2bdM3 @PeterMacCC #Immunotherapy https://t.co/zCghMVMOVp